Recursion Pharmaceuticals... (RXRX)
NASDAQ: RXRX
· Real-Time Price · USD
4.61
0.09 (1.99%)
At close: Sep 05, 2025, 3:59 PM
4.62
0.22%
After-hours: Sep 05, 2025, 07:56 PM EDT
Recursion Pharmaceuticals Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant Revenue | 120K | -73K | 48K | 26.08M | 13K | 303K | 267K | 431K | 1K | n/a | n/a | 107K | 21K | 34K | 33K | 34K | 49K | 62K |
| Grant Revenue Growth | -264.38% | -252.08% | -99.82% | +200530.77% | -95.71% | +13.48% | -38.05% | +43000.00% | n/a | n/a | -100.00% | +409.52% | -38.24% | +3.03% | -2.94% | -30.61% | -20.97% | n/a |
| License and Service Revenue | 19.1M | 14.82M | 18.91M | n/a | 14.4M | 13.49M | 10.62M | 10.1M | 11.02M | 12.13M | 13.68M | 13.05M | 7.65M | 5.3M | 2.5M | 2.5M | 2.5M | 2.5M |
| License and Service Revenue Growth | +28.92% | -21.66% | n/a | n/a | +6.77% | +26.99% | +5.17% | -8.30% | -9.21% | -11.28% | +4.77% | +70.56% | +44.42% | +111.96% | 0.00% | 0.00% | 0.00% | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|
| United States Revenue | 11.79M | 9.48M |
| United States Revenue Growth | +24.37% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 46.65M | 54.65M | 77.19M | 37.76M | 31.83M | 31.41M | 30.46M | 29.2M | 28.29M | 22.87M | 19.84M | 19.49M | 21.2M | 21.07M | 19.2M | 15.69M | 13.85M | 8.94M | 7.57M | 6.96M | 5.16M | 5.56M |
| Selling, General, and Administrative Revenue Growth | -14.63% | -29.20% | +104.43% | +18.61% | +1.35% | +3.12% | +4.31% | +3.21% | +23.68% | +15.30% | +1.80% | -8.07% | +0.59% | +9.75% | +22.38% | +13.25% | +55.02% | +18.00% | +8.76% | +34.99% | -7.23% | n/a |
| Research and Development Revenue | 128.64M | 129.63M | 98.33M | 74.6M | 70.03M | 64.16M | 66.08M | 70.01M | 55.06M | 46.68M | 43.98M | 40.84M | 38.44M | 32.44M | 48.29M | 33.25M | 29.62M | 24.11M | 20.7M | 16.54M | 13.24M | 12.84M |
| Research and Development Revenue Growth | -0.77% | +31.83% | +31.82% | +6.53% | +9.15% | -2.91% | -5.61% | +27.15% | +17.96% | +6.13% | +7.70% | +6.24% | +18.49% | -32.82% | +45.25% | +12.23% | +22.88% | +16.48% | +25.18% | +24.85% | +3.13% | n/a |